Current Report Filing (8-k)
February 27 2019 - 7:14AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported)
February
27, 2019
INTEC
PHARMA LTD.
(Exact
name of registrant as specified in its charter)
Israel
|
|
001-37521
|
|
N/A
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification
No.)
|
12
Hartom St.
Har
Hotzvim
|
|
|
Jerusalem,
Israel
|
|
9777512
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
|
+
972-2-586-4657
|
(Registrant’s
telephone number, including area code)
(Former
name or former address, if changed since last report)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act
of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this
chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒
Item
2.02 Results of Operation and Financial Condition.
On
February 27, 2019, Intec Pharma Ltd. (the “Company”) issued a press release announcing the Company’s results
of operations for the fourth quarter and fiscal year ended December 31, 2018. The press release is attached hereto as Exhibit
99.1 to this Current Report on Form 8-K and is incorporated by reference herein in its entirety.
The
information included in this Item 2.02 of Current Report on Form 8-K, including the attached Exhibit 99.1, shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report,
regardless of any general incorporation language in any such filing, except as expressly set forth by specific reference in such
filing.
Item
9.01. Financial Statement and Exhibits.
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date:
February 27, 2019
|
INTEC
PHARMA LTD.
|
|
|
|
By:
|
/s/
Nir Sassi
|
|
|
Nir
Sassi
|
|
|
Chief
Financial Officer
|
2
Intec Parent (NASDAQ:NTEC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Intec Parent (NASDAQ:NTEC)
Historical Stock Chart
From Apr 2023 to Apr 2024